It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Purine nucleoside phosphorylase (PNP) is an important enzyme in the purine degradation and salvage pathway. PNP deficiency results in marked T lineage lymphopenia and severe immunodeficiency. Additionally, PNP-deficient patients and mice suffer from diverse non-infectious neurological abnormalities of unknown etiology. To further investigate the cause for these neurologic abnormalities, induced pluripotent stem cells (iPSC) from two PNP-deficient patients were differentiated into neurons. The iPSC-derived PNP-deficient neurons had significantly reduced soma and nuclei volumes. The PNP-deficient neurons demonstrated increased spontaneous and staurosporine-induced apoptosis, measured by cleaved caspase-3 expression, together with decreased mitochondrial membrane potential and increased cleaved caspase-9 expression, indicative of enhanced intrinsic apoptosis. Greater expression of tumor protein p53 was also observed in these neurons, and inhibition of p53 using pifithrin-α prevented the apoptosis. Importantly, treatment of the iPSC-derived PNP-deficient neurons with exogenous PNP enzyme alleviated the apoptosis. Inhibition of ribonucleotide reductase (RNR) in iPSC derived from PNP-proficient neurons with hydroxyurea or with nicotinamide and trichostatin A increased the intrinsic neuronal apoptosis, implicating RNR dysfunction as the potential mechanism for the damage caused by PNP deficiency. The findings presented here establish a potential mechanism for the neurological defects observed in PNP-deficient patients and reinforce the critical role that PNP has for neuronal viability.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Hospital for Sick Children, Developmental and Stem Cell Biology Program, Toronto, Canada (GRID:grid.42327.30) (ISNI:0000 0004 0473 9646); The University to Toronto, The Institute of Medical Sciences, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938)
2 Hospital for Sick Children, Developmental and Stem Cell Biology Program, Toronto, Canada (GRID:grid.42327.30) (ISNI:0000 0004 0473 9646)
3 National Institute of Allergy and Infectious Diseases, National Institutes of Health, Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research, Bethesda, USA (GRID:grid.419681.3) (ISNI:0000 0001 2164 9667)
4 Hospital for Sick Children, Developmental and Stem Cell Biology Program, Toronto, Canada (GRID:grid.42327.30) (ISNI:0000 0004 0473 9646); The University to Toronto, The Institute of Medical Sciences, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938); The Hospital for Sick Children, Division of Immunology and Allergy, Department of Pediatrics, Toronto, Canada (GRID:grid.42327.30) (ISNI:0000 0004 0473 9646)